Press Release

FOR IMMEDIATE RELEASE  |  Global Data Route Analytics  |  September 2026

A new Global Data Route Analytics study quantifies the Global Autoinjectors Market across twelve therapy areas and more than 40 indication-level sub-segments, from anaphylaxis rescue and nerve-agent antidotes to psoriasis, migraine, multiple sclerosis, obesity and hypercholesterolemia.

The autoinjector was born as an emergency device. It is now the default delivery format for chronic therapy across immunology, metabolism, neurology and cardiovascular medicine. Global Autoinjectors Market Size, Share, Trends & Forecast 2020–2035, published by Global Data Route Analytics, values the market at USD 13,451.97 Million in 2025, rising to USD 48,029.60 Million by 2035 at a 13.57% CAGR, and breaks that revenue down across twelve therapy areas and more than 40 indication-level sub-segments.

Where the Revenue Sits, by Therapy Area (2035)

• Allergy, dermatology and immunologic disorders — the largest therapy area at USD 12,404.23 Million by 2035 (13.93% CAGR), spanning anaphylaxis rescue, food-allergy risk reduction, atopic dermatitis, psoriasis, prurigo nodularis, chronic spontaneous urticaria, hidradenitis suppurativa, bullous pemphigoid and hereditary angioedema.
• Endocrinology, metabolic and hormonal disorders — the fastest-growing at 14.29% CAGR to USD 11,116.53 Million, covering diabetes, obesity and chronic weight management, severe hypoglycaemia rescue, growth-hormone deficiency and testosterone replacement.
• Rheumatology and systemic autoimmune diseases — USD 7,546.80 Million, including rheumatoid and psoriatic arthritis, spondyloarthritis, juvenile idiopathic arthritis, lupus, giant cell arteritis and polymyalgia rheumatica.
• Neurology — USD 4,304.52 Million across multiple sclerosis, acute migraine treatment, migraine prevention, cluster headache and hATTR amyloid polyneuropathy.
• Respiratory, upper-airway and eosinophilic disorders — USD 3,926.18 Million across asthma, COPD, nasal polyps, EGPA and hypereosinophilic syndrome.
• Gastroenterology USD 2,825.02 Million; cardiovascular, lipid and renal USD 1,884.47 Million; emergency toxicology and chemical defense USD 955.50 Million; plus hematology and radiation injury, ophthalmology and sexual health.

Emergency Care Remains the Policy-Funded Floor

Anaphylaxis, opioid overdose and organophosphorus poisoning keep the emergency segment structurally funded. The report tracks school and public-access epinephrine stocking laws, HHS/ASPR's contract worth up to USD 129 million for DuoDote nerve-agent antidote autoinjectors for the Strategic National Stockpile, and BARDA's planned procurement of roughly 2 million 2-PAM autoinjectors for the CHEMPACK programme. Military, defense and government emergency-preparedness settings are quantified as a distinct end-use segment, as are emergency medical services, schools, workplaces and community public-access locations.

The same segment faces the market's most visible headwinds: the 2016 EpiPen pricing hearings, FDA and MHRA recalls of devices that failed to activate, and the approval of the first needle-free epinephrine nasal spray, which the report treats as a credible route-of-administration substitute for a portion of rescue demand.

Drug Modality Follows Therapy Area

The report cross-cuts therapy area with drug modality, quantifying small-molecule and emergency medicines (epinephrine, triptans, methotrexate, atropine, pralidoxime, naloxone and nalmefene, testosterone), therapeutic peptides and proteins (insulin, GLP-1 and dual GIP/GLP-1 agonists, glucagon, interferons, growth hormones, G-CSFs, glatiramer acetate), ten classes of monoclonal antibodies and fusion proteins, and antisense oligonucleotide therapeutics for transthyretin, kallikrein and apolipoprotein C-III targets.

Companies Profiled

Dedicated chapters cover emerging epinephrine innovators (Kaleo, ALK-Abelló, Amneal, Teva, Bioprojet, Bausch + Lomb, Pirouette Pharma, EpiSafe, Rx Bandz), allergy, emergency and anaphylaxis companies (Stallergenes Greer, Aquestive Therapeutics, Belhaven Biopharma, Viatris, HAL Allergy, LETI Pharma, Crossject), biologics and immunology drug companies (Merck, Bristol Myers Squibb, Boehringer Ingelheim, GSK, Regeneron, Genentech, CSL Behring, Grifols, Sobi) and the device, container and CDMO partners behind them.

About the Report

The 1,750-page study quantifies the Global Autoinjectors Market across twelve segmentation axes, five regions and 31 countries, includes a dedicated ten-dimension price-analysis chapter and profiles 151 companies across 15 chapters covering device manufacturers, platform and injection-technology companies, pharma users, biosimilar and specialty-injectable companies, connected-device, CDMO, primary-container, safety-syringe, automation and regional emerging-market companies. Deliverables include a 700+ table PDF and an Excel data pack with verified company and product links.

About Global Data Route Analytics

Global Data Route Analytics is a market research and consulting firm delivering syndicated and custom research across healthcare, life sciences, medical devices and adjacent industries. Our reports combine primary interviews, verified secondary sources and proprietary estimation models to give manufacturers, investors and policy teams a quantified basis for decisions.

Report: Global Autoinjectors Market Size, Share, Trends & Forecast 2020–2035

Media & Sales Contact: Global Data Route Analytics  |  globaldatarouteanalytics.com/contact